Welcome to BioMarin’s Investor Relations & Media Page

We’ve brought together a variety of information in one location to better assist you in your efforts to research and develop news articles and learn about our company.

BioMarin Pharmaceutical Inc. was founded in 1997, and since July 1999 the company's common stock has been traded on the Nasdaq National Market under the ticker symbol BMRN. BioMarin's policy is to fully comply with all rules put forth by the Securities and Exchange Commission and the Nasdaq National Market. For misplaced stock certificates, please contact our transfer agent directly.

Recent News
Jan 10, 2021
BioMarin Announces Positive Phase 3 Gene Therapy Trial Results in Adults with Severe Hemophilia A; Study Met All Primary and Secondary Efficacy Endpoints in One-Year Data Set

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced positive topline results from its ongoing global Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, an investigational gene therapy...

Jan 5, 2021
BioMarin to Participate in Two Upcoming Virtual Investor Conferences

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in two upcoming virtual conferences. An audio webcast of the presentations will be available live. You...

Dec 21, 2020
BioMarin Announces Benefit Maintained for Over Two Years in Children with Achondroplasia Treated with Vosoritide in Phase 3 Extension Study

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that children in the open-label long-term extension of the Phase 3 study of vosoritide, an investigational, once daily injection analog...

Events & Presentations
J.P. Morgan 39th Annual Healthcare Conference
Monday, January 11, 2021
11:40am - 12:20pm EST
Valoctocogene Roxaparvovec Phase 3 One-year Results Conference Call
Sunday, January 10, 2021
7:15pm - 8:00pm EST

Stock Quote
NASDAQBMRN